Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. [electronic resource]
Producer: 20170613Description: 75-87 p. digitalISSN:- 1474-5488
- Aged
- Antineoplastic Agents -- pharmacology
- BRCA1 Protein -- genetics
- BRCA2 Protein -- genetics
- Carcinoma, Ovarian Epithelial
- Drug Resistance, Neoplasm -- drug effects
- Fallopian Tube Neoplasms -- drug therapy
- Female
- Follow-Up Studies
- Germ-Line Mutation -- genetics
- Humans
- Indoles -- therapeutic use
- International Agencies
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Neoplasm Staging
- Neoplasms, Glandular and Epithelial -- drug therapy
- Ovarian Neoplasms -- drug therapy
- Peritoneal Neoplasms -- drug therapy
- Platinum -- pharmacology
- Poly(ADP-ribose) Polymerase Inhibitors -- therapeutic use
- Poly(ADP-ribose) Polymerases -- chemistry
- Prognosis
- Prospective Studies
- Salvage Therapy
- Survival Rate
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.